CNBX Pharmaceuticals Inc. (CNBX) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CNBX representa a CNBX Pharmaceuticals Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 37/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026CNBX Pharmaceuticals Inc. (CNBX) Resumen de Asistencia Médica y Tuberías
CNBX Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of cannabinoid-based treatments for various cancers, including colorectal, breast, melanoma, and prostate. Their lead product, RCC-33, is an oral capsule targeting colorectal cancer, positioning them within the competitive biotechnology landscape.
Tesis de Inversión
CNBX Pharmaceuticals Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cannabinoid-based cancer treatments offers potential for significant growth, particularly if RCC-33 or other pipeline drugs demonstrate efficacy and gain regulatory approval. However, the company's small market capitalization of $0.00B and negative P/E ratio of -0.19 indicate substantial financial challenges. Successful clinical trials and securing partnerships will be critical for CNBX to realize its potential. The development and commercialization of Cannabics CDx, an ex-vivo drug sensitivity test, could provide a revenue stream and validate their technology. Investors should closely monitor clinical trial results and funding activities.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- CNBX Pharmaceuticals Inc. is focused on cannabinoid-based treatments for cancer.
- Lead product candidate RCC-33 targets colorectal cancer.
- Developing drug candidates for breast cancer, melanoma, and prostate cancer.
- Market Cap is $0.00B as of 2026-03-16.
- P/E ratio is -0.19, indicating the company is not currently profitable.
Competidores y Pares
Fortalezas
- Focus on cannabinoid-based cancer treatments.
- Pipeline of drug candidates targeting various cancers.
- Development of Cannabics CDx for personalized medicine.
- Proprietary cannabinoid formulations.
Debilidades
- Limited financial resources.
- Small market capitalization.
- Dependence on successful clinical trials.
- Regulatory hurdles for cannabinoid-based therapies.
Catalizadores
- Upcoming: Clinical trial results for RCC-33 in colorectal cancer treatment.
- Upcoming: Development updates and potential commercialization of Cannabics CDx.
- Upcoming: Potential partnerships or collaborations with larger pharmaceutical companies.
- Ongoing: Research and development progress in cannabinoid-based therapies for various cancers.
Riesgos
- Potential: Failure of clinical trials for RCC-33 or other drug candidates.
- Potential: Regulatory hurdles and changing regulations for cannabinoid-based therapies.
- Ongoing: Limited financial resources and difficulty securing funding.
- Ongoing: Competition from established pharmaceutical companies in the cancer treatment market.
- Potential: Low liquidity and high volatility due to trading on the OTC market.
Oportunidades de crecimiento
- Expansion of Clinical Trials: CNBX has the opportunity to expand clinical trials for its lead product candidate, RCC-33, into larger patient populations and different geographical locations. Successful completion of these trials could lead to regulatory approval and commercialization, opening up a significant market opportunity in colorectal cancer treatment. The global colorectal cancer therapeutics market is projected to reach billions of dollars by 2030, presenting a substantial revenue potential for CNBX.
- Development of Cannabics CDx: The development and commercialization of Cannabics CDx, an ex-vivo drug sensitivity test, represents a significant growth opportunity for CNBX. This test could help personalize cancer treatment by identifying patients most likely to respond to cannabinoid-based therapies. The market for personalized medicine and diagnostics is rapidly expanding, driven by advances in genomics and precision medicine. Successful commercialization of Cannabics CDx could generate revenue and enhance the company's reputation.
- Partnerships and Collaborations: CNBX could pursue partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its drug candidates. These collaborations could provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its products to market. Strategic alliances can significantly reduce the financial burden and timeline associated with drug development.
- Expansion into New Therapeutic Areas: CNBX could expand its research and development efforts into new therapeutic areas beyond cancer, such as pain management or neurological disorders. Cannabinoids have shown promise in treating a variety of conditions, and diversifying its pipeline could reduce the company's reliance on cancer therapeutics. This expansion could open up new market opportunities and attract a broader range of investors.
- Geographic Expansion: CNBX has the opportunity to expand its operations into new geographic markets, particularly in regions with favorable regulatory environments for cannabinoid-based therapies. Europe and Canada are examples of markets where cannabis-based medicines are increasingly accepted. Expanding into these markets could increase the company's revenue and global presence. Navigating international regulations will be key to success.
Oportunidades
- Expansion of clinical trials.
- Partnerships with larger pharmaceutical companies.
- Commercialization of Cannabics CDx.
- Expansion into new therapeutic areas.
Amenazas
- Competition from established pharmaceutical companies.
- Regulatory changes affecting cannabinoid-based therapies.
- Failure of clinical trials.
- Difficulty securing funding.
Ventajas competitivas
- Proprietary cannabinoid formulations and drug delivery systems.
- Intellectual property protection through patents and trademarks.
- First-mover advantage in the cannabinoid-based cancer treatment market.
- Expertise in cannabinoid research and development.
Acerca de CNBX
CNBX Pharmaceuticals Inc., formerly known as Cannabics Pharmaceuticals Inc., was founded in 2004 and is based in Bethesda, Maryland. The company is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Their lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids designed for the treatment of colorectal cancer. In addition to RCC-33, CNBX is developing a pipeline of drug candidates targeting various forms of cancer. These include PLP-33 for the treatment of lateral spreading or sessile colorectal polyps during colonoscopy, BRST-33 to treat breast cancer, MLN-33 for the treatment of Melanoma, and PRST-33 to treat prostate cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome, and Cannabics CDx, an ex-vivo drug sensitivity test. CNBX Pharmaceuticals Inc. operates as a subsidiary of Cannabics Inc., focusing on innovative approaches to cancer treatment through cannabinoid-based therapies.
Qué hacen
- Develop cannabinoid-based treatments for cancer.
- Focus on therapies for colorectal, breast, melanoma, and prostate cancers.
- Develop ex-vivo drug sensitivity tests.
- Research and develop novel cannabinoid formulations.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Seek regulatory approvals for their products.
Modelo de Negocio
- Develop and patent cannabinoid-based drug formulations.
- Conduct research and development to advance drug candidates through clinical trials.
- Seek partnerships or out-licensing agreements with larger pharmaceutical companies.
- Potentially manufacture and market approved drugs directly or through partners.
Contexto de la Industria
CNBX Pharmaceuticals Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. The company's focus on cannabinoid-based treatments differentiates it from traditional pharmaceutical companies, but also introduces regulatory and market acceptance hurdles. Competitors like ACUR, AFFY, ENDV, FLHLF, and GNLKQ are also active in the biotechnology space, some with overlapping therapeutic areas.
Clientes Clave
- Cancer patients seeking alternative or complementary treatments.
- Oncologists and other healthcare professionals.
- Pharmaceutical companies interested in licensing or acquiring novel cancer therapies.
- Research institutions and universities.
Finanzas
Gráfico e información
Precio de la acción de CNBX Pharmaceuticals Inc. (CNBX): Price data unavailable
Últimas noticias
-
CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Short Interest Update
defenseworld.net · 1 feb 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· 29 ene 2020
-
Stocks That Hit 52-Week Lows On Friday
· 6 dic 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CNBX.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CNBX.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CNBX en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Últimas Noticias
Liderazgo: Eyal Barad
CEO
Eyal Barad serves as the CEO of CNBX Pharmaceuticals Inc. His background includes experience in managing small teams, as evidenced by his role in overseeing the company's single employee. Further details regarding his educational background and previous roles are not available, but his leadership is focused on guiding CNBX Pharmaceuticals Inc. through its drug development pipeline.
Historial: Under Eyal Barad's leadership, CNBX Pharmaceuticals Inc. has focused on advancing its lead product candidate, RCC-33, and developing other cannabinoid-based treatments for various cancers. His tenure has involved navigating the challenges of a small biopharmaceutical company in a competitive industry, with a focus on research and development. Specific milestones and achievements are not detailed in the provided data.
Información del mercado OTC de CNBX
The OTC Other tier represents the lowest tier of the OTC market, indicating that CNBX Pharmaceuticals Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may not be subject to regular audits or filings with the SEC, unlike companies listed on major exchanges like the NYSE or NASDAQ. This lack of stringent requirements increases the risk for investors.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Financial Disclosure: OTC companies often have less stringent financial reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: Trading volume can be very low, leading to wide bid-ask spreads and difficulty in buying or selling shares.
- Increased Volatility: OTC stocks are often more volatile than those listed on major exchanges.
- Potential for Fraud: The lack of regulatory oversight increases the risk of fraudulent activities.
- Going Concern Risk: Companies on the OTC Other tier may have limited operating history and financial resources, raising concerns about their ability to continue as a going concern.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's capital structure and debt levels.
- Understand the company's regulatory environment and compliance requirements.
- Consult with a qualified financial advisor.
- Company is a subsidiary of Cannabics Inc.
- Focus on cannabinoid-based cancer treatments.
- Development of a pipeline of drug candidates.
- Incorporated in 2004, indicating some operating history.
Lo Que los Inversores Preguntan Sobre CNBX Pharmaceuticals Inc. (CNBX)
¿Cuáles son los factores clave para evaluar CNBX?
CNBX Pharmaceuticals Inc. (CNBX) actualmente tiene una puntuación IA de 37/100, indicando puntuación baja. Fortaleza clave: Focus on cannabinoid-based cancer treatments.. Riesgo principal a monitorear: Potential: Failure of clinical trials for RCC-33 or other drug candidates.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CNBX?
CNBX actualmente puntúa 37/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CNBX?
Los precios de CNBX se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CNBX?
La cobertura de analistas para CNBX incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CNBX?
Las categorías de riesgo para CNBX incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure of clinical trials for RCC-33 or other drug candidates.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CNBX?
La relación P/E para CNBX compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CNBX sobrevalorada o infravalorada?
Determinar si CNBX Pharmaceuticals Inc. (CNBX) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CNBX?
CNBX Pharmaceuticals Inc. (CNBX) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on the company's financial performance and operations.
- OTC market carries higher risks than major exchanges.